ClinicalTrials.gg
CompletedNCT00485303Updated Jul 2, 2013Results posted

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

A Phase 2 interventional study of Abiraterone acetate and Prednisone in Prostatic Neoplasms and Prostate Cancer, sponsored by Cougar Biotechnology, Inc.. Completed at 14 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-02.

Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
46th of 98
58 · median 56
Started
2007
with 3 others
Phase 2
59 of 98
9 open now
Registered
4th of 98
by date
Lead sponsor
6 of 98
Cougar Biotechnology, Inc.

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 46th largest by enrollment, is one of 4 that started in 2007, is one of 59 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).

Read the detailed description

This is an open-label (all people know the identity of the intervention), single-arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy. Abiraterone acetate oral tablet will be administered as a total dose of 1000 milligram (mg) orally (by mouth) once daily after an overnight fast and prednisone/prednisolone will be administered as 5 mg oral tablet twice daily. Participants will be enrolled and treated up to 12 cycles (or longer, if they have not progressed and continue to benefit from treatment). The study will consist of 3 parts: Screening (14 days), Open-label Treatment; and follow-up (up to 60 months). Participants will be evaluated primarily for prostate specific antigen response according to Prostate Specific Antigen Working Group (PSAWG) criteria. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostatic Neoplasms
  • Prostate Cancer

Browse trials for

Keywords

  • Prostatic Neoplasms
  • Prostate cancer
  • Abiraterone acetate
  • CB7630
  • Prednisone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma (malignant epithelial tumor with a glandular organization)of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum), but not with neuroendocrine (specialized neurons that produce hormones, such as neuropeptides or biogenic amines) differentiation or of small cell histology
  • Prior chemotherapy (treatment of disease, usually cancer, by chemical agents) for prostate cancer with regimen(s) containing docetaxel
  • Documented prostate specific antigen (PSA) progression according to Prostate Specific Antigen Working Group (PSAWG) eligibility criteria with a PSA more than (>) 5 nanogram per milliliter (ng/mL) or objective progression by (RESIST) criteria
  • Ongoing androgen deprivation with serum testosterone less than (\<) 50 nanogram per deciliter (ng/dL)
  • (ECOG) Performance Status of less than equal to (\<=) 2 ( Performance Status >= 50 percent)

Exclusion criteria

Exclusion Criteria:

  • Active or uncontrolled disease (disorder in which a person's immune system attacks parts of his or her own body) that may require therapy
  • Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  • Uncontrolled hypertension (high blood pressure)
  • \<=9.0 gram per deciliter (g/dL) without growth factor or transfusion support
  • Abnormal liver (large organ that helps in many body functions, including digestion, metabolism, and storage of substances) function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Abiraterone

    Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.

    Drug: Abiraterone acetate · Drug: Prednisone

Interventions

  • Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.

  • Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.

    Also known as: CB7630

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Prostate Specific Antigen (PSA) Response

    The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.

    Time frame: Day 1 of each cycle (of 28 days each) up to Cycle 12

Secondary outcomes

  1. Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS)

    The PSA-PFS is defined as time to first PSA failure (that is, two consecutive increases in PSA of 50 percent and greater than or equal to 5 nanogram per milliliter, as per Prostate-Specific Antigen Working Group \[PSAWG\] criterion) or death or the start of secondary anti-tumor therapy, whichever occurs first. If a PSA progression or death does not occur, subject will be censored at the last PSA evaluation.

    Time frame: Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months

  2. Radiographic Progression Free Survival (PFS)

    The RAD-PFS is defined as the time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months

  3. Overall Survival (OS)

    Overall survival is defined as the interval from the date of the first dose of abiraterone acetate to the date of death.

    Time frame: Every 3 months until death or up to 60 months

  4. Percentage of Participants With Objective Radiographic Response

    Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months

  5. Time to PSA Progression

    The time interval from first dose of abiraterone acetate to the date of PSA progression as defined by the Prostate-Specific Antigen Working Group (PSAWG) criteria. If a PSA progression does not occur, subject will be censored at the last PSA evaluation.

    Time frame: Day 8 of Cycle 1, thereafter Day 1 of each cycle up to end of study (60 months)

  6. Time to Radiographic Progression

    Time to radiographic progression is defined as the time from first dose until the first radiographic progression date that was confirmed.

    Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months

  7. Shift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score

    ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature, 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50 percent of waking hours, 3=capable of limited self-care, confined to bed or chair \>50 percent of waking hours, 4=completely disabled, not capable of any self-care, totally confined to bed or chair and 5=dead.

    Time frame: Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months

  8. Percentage of Participants With Clinical Benefit

    Clinical benefit was defined as an observation of at least 1 of the following: PSA response by PSAWG criteria; radiographic response by RECIST criteria; stable disease by RECIST criteria lasting 6 months; or improvement by at least 1 unit in ECOG performance status.

    Time frame: Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months

07

Results

Posted Jun 17, 2013

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone
Started58
Completed2
Not completed56
Withdrew: Adverse event5
Withdrew: Progressive disease44
Withdrew: Other3
Withdrew: Initiation of new anti-cancer treatment2
Withdrew: Treatment ongoing at cutoff date2

Outcome measures

PrimaryPercentage of Participants With Prostate Specific Antigen (PSA) Response

The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.

Time frame:
Day 1 of each cycle (of 28 days each) up to Cycle 12
Reported as:
Number · percentage of participants
Percentage of Participants With Prostate Specific Antigen (PSA) Response
percentage of participantsAbiraterone
Percentage of Participants With Prostate Specific Antigen (PSA) Response37.9 (25.5 to 51.6)
SecondaryProstate-Specific Antigen Based Progression-free Survival (PSA-PFS)

The PSA-PFS is defined as time to first PSA failure (that is, two consecutive increases in PSA of 50 percent and greater than or equal to 5 nanogram per milliliter, as per Prostate-Specific Antigen Working Group \[PSAWG\] criterion) or death or the start of secondary anti-tumor therapy, whichever occurs first. If a PSA progression or death does not occur, subject will be censored at the last PSA evaluation.

Time frame:
Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months
Reported as:
Median · days
Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS)
daysAbiraterone
Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS)141 (110 to 200)
SecondaryRadiographic Progression Free Survival (PFS)

The RAD-PFS is defined as the time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Reported as:
Median · days
Radiographic Progression Free Survival (PFS)
daysAbiraterone
Radiographic Progression Free Survival (PFS)126 (82 to 333)
SecondaryOverall Survival (OS)

Overall survival is defined as the interval from the date of the first dose of abiraterone acetate to the date of death.

Time frame:
Every 3 months until death or up to 60 months
Reported as:
Median · days
Overall Survival (OS)
daysAbiraterone
Overall Survival (OS)492 (373 to 647)
SecondaryPercentage of Participants With Objective Radiographic Response

Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Radiographic Response
percentage of participantsAbiraterone
Complete response (CR)0
Partial Response (PR)6.3
SecondaryTime to PSA Progression

The time interval from first dose of abiraterone acetate to the date of PSA progression as defined by the Prostate-Specific Antigen Working Group (PSAWG) criteria. If a PSA progression does not occur, subject will be censored at the last PSA evaluation.

Time frame:
Day 8 of Cycle 1, thereafter Day 1 of each cycle up to end of study (60 months)
Reported as:
Median · days
Time to PSA Progression
daysAbiraterone
Time to PSA Progression169 (99 to 225)
SecondaryTime to Radiographic Progression

Time to radiographic progression is defined as the time from first dose until the first radiographic progression date that was confirmed.

Time frame:
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Reported as:
Median · days
Time to Radiographic Progression
daysAbiraterone
Time to Radiographic Progression88 (82 to 333)
SecondaryShift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score

ECOG performance status score ranges from 0 to 5 where 0=fully active, perform all pre-disease activities without restriction. 1=restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature, 2=ambulatory, capable of self-care, unable to carry out any work activities, up and about more than (\>) 50 percent of waking hours, 3=capable of limited self-care, confined to bed or chair \>50 percent of waking hours, 4=completely disabled, not capable of any self-care, totally confined to bed or chair and 5=dead.

Time frame:
Baseline and Day 1 of each cycle until first documented disease progression or up to 60 months
Reported as:
Number · participants
Shift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score
participantsAbiraterone
Baseline:0; Best Post-dose:022
Baseline:0; Best Post-dose:12
Baseline:0; Best Post-dose:20
Baseline:0; Best Post-dose:30
Baseline:0; Best Post-dose:40
Baseline:1; Best Post-dose:014
Baseline:1; Best Post-dose:115
Baseline:1; Best Post-dose:22
Baseline:1; Best Post-dose:30
Baseline:1; Best Post-dose:40
Baseline:2; Best Post-dose:01
Baseline:2; Best Post-dose:11
Baseline:2; Best Post-dose:20
Baseline:2; Best Post-dose:30
Baseline:2; Best Post-dose:40
Baseline:0; Worst Post-dose:06
Baseline:0; Worst Post-dose:117
Baseline:0; Worst Post-dose:21
Baseline:0; Worst Post-dose:30
Baseline:0; Worst Post-dose:40
Baseline:1; Worst Post-dose:00
Baseline:1; Worst Post-dose:124
Baseline:1; Worst Post-dose:26
Baseline:1; Worst Post-dose:31
Baseline:1; Worst Post-dose:40
Baseline:2; Worst Post-dose:00
Baseline:2; Worst Post-dose:10
Baseline:2; Worst Post-dose:22
Baseline:2; Worst Post-dose:30
Baseline:2; Worst Post-dose:40
SecondaryPercentage of Participants With Clinical Benefit

Clinical benefit was defined as an observation of at least 1 of the following: PSA response by PSAWG criteria; radiographic response by RECIST criteria; stable disease by RECIST criteria lasting 6 months; or improvement by at least 1 unit in ECOG performance status.

Time frame:
Baseline, Day 1 of Cycle 4, 7 and 10, and thereafter every third cycle until first documented disease progression or up to 60 months
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit
percentage of participantsAbiraterone
Disease Stabilization12
Change in participant ECOG score16

Adverse events

Collected over Day 8 of Cycle 1 up to End of Study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone—23/58 (39.7%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventAbiraterone
PyrexiaGeneral disorders4/58
Back painMusculoskeletal and connective tissue disorders4/58
Atrial fibrillationCardiac disorders2/58
FatigueGeneral disorders2/58
PneumoniaInfections and infestations2/58
Haemoglobin decreasedInvestigations2/58
Muscular weaknessMusculoskeletal and connective tissue disorders2/58
Pain in extremityMusculoskeletal and connective tissue disorders2/58
DizzinessNervous system disorders2/58
Spinal cord compressionNervous system disorders2/58
Most frequent other events
Showing 10 of 50
Most frequent other events
EventAbiraterone
FatigueGeneral disorders23/58
Oedema peripheralGeneral disorders18/58
AnaemiaBlood and lymphatic system disorders15/58
ConstipationGastrointestinal disorders15/58
Aspartate aminotransferase increasedInvestigations15/58
Back painMusculoskeletal and connective tissue disorders15/58
ArthralgiaMusculoskeletal and connective tissue disorders13/58
Blood albumin decreasedInvestigations12/58
HyperglycaemiaMetabolism and nutrition disorders12/58
NauseaGastrointestinal disorders11/58

Baseline characteristics

Age Continuous
Age Continuous(Years)Abiraterone
Mean68.6 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone
Female0
Male58
Region of Enrollment
Region of Enrollment(Participants)Abiraterone
United Kingdom4
United States54
08

Study locations

14 sites
  • UCLA
    Los Angeles, California 90024, United States
  • Los Angeles, California, United States
  • UCSF Comprehensive Cancer Center
    San Francisco, California 94115, United States
  • San Francisco, California, United States
  • John Hopkins
    Baltimore, Maryland 21205, United States
  • Baltimore, Maryland, United States
  • Masachussetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Beth Israel Hospital
    Boston, Massachusetts 02215, United States
  • Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • New York, New York, United States
  • Royal Marsden Hospital
    Sutton, United Kingdom
  • Sutton, United Kingdom
09

References and documents

Publications

  • Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011 Nov;60(5):897-904. doi: 10.1016/j.eururo.2011.07.011. Epub 2011 Jul 14. PubMed 21802835 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2007
First posted
Jun 12, 2007
Start
Jun 2007
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jun 17, 2013
Last update
Jul 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00485303
Responsible party
Sponsor
First posted
Jun 12, 2007
Start date
Jun 2007
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jun 17, 2013
Last update
Jul 2, 2013

Study contacts

Cougar Biotechnology, Inc. Clinical Trial
study director · Cougar Biotechnology, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion